Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2014-04-25 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
内部控制鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制鉴证报告" (Internal Control Assurance Report) for Beijing SL Pharmaceutical Co., Ltd., dated April 24, 2014, covering the internal control evaluation as of December 31, 2013. It is issued by a certified public accounting firm and includes detailed descriptions of the company's internal control environment, risk assessment, control activities, information and communication, and internal supervision. The document focuses on the effectiveness of internal controls related to financial reporting and operational processes, with no financial statements or earnings data presented. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and internal control evaluations, excluding full annual reports. The document length is substantial (over 13,000 characters), indicating it is the report itself, not just an announcement. Therefore, the appropriate classification is AR with high confidence. FY 2013
2014-04-25 Chinese
第五届监事会第七次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Beijing Shuanglu Pharmaceutical Co., Ltd. It details the approval of various reports including the 2013 Supervisory Board Work Report, 2013 Financial Final Report, 2013 Profit Distribution Plan, 2013 Annual Report and Summary, and the 2014 Q1 Report. It also includes approvals related to internal control evaluation, audit firm reappointment, related party transactions, and use of idle funds for short-term low-risk investments. The document is a formal announcement of meeting resolutions and approvals rather than the full reports themselves. The document length is short (2016 characters) and it references reports to be submitted to the shareholders' meeting, indicating it is an announcement of decisions rather than the reports. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution notice rather than a full Annual Report (10-K) or Interim Report (IR).
2014-04-25 Chinese
关于全资子公司对中科生物制药股份有限公司委托贷款的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a loan transaction between a company's wholly owned subsidiary and another company. It details the loan amount, terms, risk assessment, decision-making process, and independent director opinions. It does not contain financial statements or comprehensive financial performance data. The document is a formal announcement of a financing activity (loan) rather than a full financial report or audit. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is under 5,000 characters, but it contains substantive details about the financing, not just a notice of report publication or certification, so it is not RPA or RNS.
2014-04-25 Chinese
控股股东及其他关联方资金占用情况的专项说明
Audit Report / Information Classification · 95% confidence The document is a special explanation report regarding the use of funds by controlling shareholders and other related parties of Beijing Shuanglu Pharmaceutical Co., Ltd. It is issued by Da Hua Certified Public Accountants and references the audit of the 2013 financial statements, including balance sheets and profit statements. The document cites regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange related to disclosure of related party transactions and fund occupation. It includes a detailed summary table of fund occupation as of December 31, 2013. The document is a standalone audit-related report focusing on a specific issue (related party fund occupation) rather than a full annual report or interim report. It is not a mere announcement or certification but contains substantive audited financial data related to the specific topic. Therefore, it fits the definition of an Audit Report / Information (AR) which includes standalone audit reports and related disclosures excluding full annual reports. FY 2013
2014-04-25 Chinese
2013年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2013 年度报告摘要" which translates to "2013 Annual Report Summary". It contains detailed financial data for the year 2013, including revenue, net profit, earnings per share, and asset information. It also includes management discussion and analysis of the company's operations, business segments, and shareholder information. The document is over 7,000 characters, indicating it is substantive and not merely an announcement or a brief summary. The content aligns with the characteristics of an Annual Report, providing a comprehensive overview of the company's yearly performance and business activities. Therefore, the document should be classified as an Annual Report (10-K). FY 2013
2014-04-25 Chinese
关于使用自有资金进行短期低风险投资事项的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Beijing SL Pharmaceutical Co., Ltd. regarding the company's decision to use its own funds for short-term low-risk investments. It details the investment purpose, amount, objects, approval procedures, impact on the company, risk control measures, and opinions from independent directors and the supervisory board. The document is an announcement of a corporate financing or capital management activity, specifically about the use of company funds for investment purposes. It does not contain financial statements or detailed financial results, nor is it a report or transcript. It is not a regulatory certification or a voting result announcement. The content fits best under Capital/Financing Update (CAP) as it updates on the company's financing activities and capital usage.
2014-04-25 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.